89Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast Tumors - Wikidata - wikimedia - TriplyDB

89Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast Tumors

89Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast Tumors

http://www.wikidata.org/entity/Q37148669

about

In Vivo Integrity and Biological Fate of Chelator-Free Zirconium-89-Labeled Mesoporous Silica Nanoparticles.Exploiting the Metal-Chelating Properties of the Drug Cargo for In Vivo Positron Emission Tomography Imaging of Liposomal Nanomedicines.Evaluation of (89)Zr-pertuzumab in Breast cancer xenografts.Tripodal tris(hydroxypyridinone) ligands for immunoconjugate PET imaging with (89)Zr(4+): comparison with desferrioxamine-B.A modular labeling strategy for in vivo PET and near-infrared fluorescence imaging of nanoparticle tumor targeting Novel Bifunctional Cyclic Chelator for (89)Zr Labeling-Radiolabeling and Targeting Properties of RGD Conjugates PET Imaging of Tumor-Associated Macrophages with 89Zr-Labeled High-Density Lipoprotein Nanoparticles [(64) Cu]-labelled trastuzumab: optimisation of labelling by DOTA and NODAGA conjugation and initial evaluation in mice.H6phospa-trastuzumab: bifunctional methylenephosphonate-based chelator with 89Zr, 111In and 177Lu.Siderophores for molecular imaging applications.(89)Zr, a radiometal nuclide with high potential for molecular imaging with PET: chemistry, applications and remaining challenges.Matching chelators to radiometals for radiopharmaceuticals.Zirconium-89 labeled antibodies: a new tool for molecular imaging in cancer patients.Exploiting the biosynthetic machinery of Streptomyces pilosus to engineer a water-soluble zirconium(iv) chelator.Macrocycle-Based Hydroxamate Ligands for Complexation and Immunoconjugation of 89Zirconium for Positron Emission Tomography (PET) Imaging.Cyclic versus Noncyclic Chelating Scaffold for 89Zr-Labeled ZEGFR:2377 Affibody Bioconjugates Targeting Epidermal Growth Factor Receptor Overexpression.Improved Tumor Penetration and Single-Cell Targeting of Antibody Drug Conjugates Increases Anticancer Efficacy and Host Survival.A new tetrapodal 3-hydroxy-4-pyridinone ligand for complexation of 89zirconium for positron emission tomography (PET) imaging.Rational Design, Development, and Stability Assessment of a Macrocyclic Four-Hydroxamate-Bearing Bifunctional Chelating Agent for 89 Zr.

P2860

Q27342269-5428F557-D5C3-4F52-AEAD-84EAFC91D853 Q30829681-7C74BC28-CB28-4C49-8F01-CE7D7DE54F0E Q34473478-913F2E82-3C87-4710-A524-D747F6A75728 Q35170338-376595FD-4D62-4331-A31C-5F8BFF31D700 Q35238675-0AF532EF-86F4-41CC-A5B0-0EC6EE590411 Q35676322-8300985F-F5A3-402C-A8AA-B95791446E49 Q36533549-8D804A79-4AC4-4AA2-8401-858C16C4F9B4 Q37268891-7052A49E-D2BA-4860-B293-BD1E2BBB410A Q37412579-04348A9A-0B7E-487E-BC4F-964560772DD0 Q37609134-1745B76C-EE1E-4BB7-A343-9B47BB35F134 Q38111973-B6DE32CC-BB7C-434D-9E79-3226F0DA212C Q38156660-C6A41741-D912-4D10-A3DD-18268F31363B Q38225877-12E0FA0D-4F9B-450F-B78A-B404EF743B40 Q38709042-BEB30DC2-5098-4415-8849-6107F5878F44 Q41067900-20812F29-C9E2-400F-806F-284B521D6190 Q47158578-770E1A45-7F12-4C84-98C4-BD5535412709 Q47271330-A0B2B5DC-9377-45A4-BEF9-2E957BC46937 Q48118923-F927F839-9572-4531-8745-E42DDC2FFD31 Q48719577-6F04EF80-DFB5-4851-9E37-F882091D7471

P2860

89Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast Tumors

http://www.wikidata.org/entity/Q37148669

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 05 January 2012

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

89Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast Tumors

@en

89Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast Tumors.

@nl

type

label

89Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast Tumors

@en

89Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast Tumors.

@nl

prefLabel

89Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast Tumors

@en

89Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast Tumors.

@nl

P1433

Q37148669-D3639A1B-4053-43AA-B4DE-69ED07E16518

P1476

Q37148669-9F33CC10-573A-49E3-8034-070B0A261A13

P2093

Q37148669-3FD6602D-109A-4955-A0C2-A99318EBEB35

Q37148669-545B433A-E9E7-4304-B83F-5F111B4067BC

Q37148669-7A621425-C395-46FC-92F4-EF19F6110421

Q37148669-977B604C-DBC5-42DC-9F5E-0D8D824657EF

P2860

Q37148669-09186FB1-0C1F-4AD7-AABE-56D97B0E9E0F

Q37148669-0DD85D36-16F8-4C02-9637-C498356F5AFE

Q37148669-0E11F521-E5DA-4EDD-9E5E-A6DDA735BA86

Q37148669-0E335664-5DC1-4D7D-9097-7DFBADCB6907

Q37148669-100C8D4F-8B27-4283-94E0-A9DEC1137943

Q37148669-11C23C91-A94D-4B61-B5A6-D25FADB18814

Q37148669-1409B164-63DE-46BE-B172-52CA326F4B59

Q37148669-3EC91A28-046B-4ACA-9293-721809D8925D

Q37148669-4A675F32-6AFF-4275-85F1-41DCD78E9404

Q37148669-55077F04-28FE-4B45-A180-DFF93BCDBEB5

P304

Q37148669-89527EEB-0656-49F5-9DE3-6FEA11AE4436

P31

Q37148669-0288106E-30FD-47B9-9FF8-BBBA8276BA9B

P356

Q37148669-60EA30CF-6466-4E75-AA07-1B003BF7DA86

P433

Q37148669-D814FC6E-B36E-486B-B667-95EA5C4183E6

P478

Q37148669-71AF5EB2-7455-49E8-9F80-545B16B4D7E5

P50

Q37148669-57DAD5A3-5A50-4E21-9846-68145A41E097

Q37148669-9AC197C5-62B1-4180-88C1-B73D018F14F8

P577

Q37148669-45441986-7B59-4B95-86A2-112E76C81219

P5875

Q37148669-5E9CB0E7-041A-4C92-AE28-F783F85289FE

P698

Q37148669-D766E8F8-B483-4CDF-ACF7-3D6423C8DEDE

P932

Q37148669-6B1A5CE9-195D-4B11-8E38-B5642E3530D4

P356

P1433

Pharmaceuticals

P1476

89Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast Tumors

@en

P2093

Albert J Chang

http://www.w3.org/2001/XMLSchema#string

Buck Rogers

http://www.w3.org/2001/XMLSchema#string

Kimberley Lears

http://www.w3.org/2001/XMLSchema#string

Ravindra Desilva

http://www.w3.org/2001/XMLSchema#string

P2860

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

EGF-ERBB signalling: towards the systems level

Heterogeneous gene alterations in primary breast cancer contribute to discordance between primary and asynchronous metastatic/recurrent sites: HER2 gene amplification and p53 mutation.

Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab

Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review

PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors.

p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging

Targeting HER2: a report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials.

P304

79-93

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3390/PH5010079

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-01-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259003296

http://www.w3.org/2001/XMLSchema#string

P698

24288044

http://www.w3.org/2001/XMLSchema#string

P932

3763623

http://www.w3.org/2001/XMLSchema#string